Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.59 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | TDO2 | P48775 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031333 | 1.00 | CTRB1 (0.59) | CTRB1PPARAPPARGCTSKTACR1 | |
| SCHEMBL6534777 | 1.00 | CTRB1 (0.59) | CTRB1PPARAPPARGCTSKTACR1 | |
| SCHEMBL30788991 | 0.91 | CTRB1 (0.59) | CTRB1CTSKTACR1CTSLCTSB | |
| SCHEMBL29473472 | 0.91 | TACR1 (0.61) | CTRB1CTSKTACR1CTSLCTSB | |
| SCHEMBL8336670 | 0.88 | CTSL (0.58) | CTRB1CTSKTACR1CTSLCTSB | |
| SCHEMBL2416694 | 0.88 | CTRB1 (0.67) | CTRB1PPARAPPARGCTSKTACR1 | |
| SCHEMBL6568131 | 0.88 | CTRB1 (0.67) | CTRB1PPARAPPARGCTSKTACR1 | |
| SCHEMBL9544107 | 0.88 | CTRB1 (0.67) | CTRB1PPARAPPARGCTSKTACR1 | |
| SCHEMBL8387978 | 0.88 | FOLH1 (0.65) | PPARAPPARGCTSKFOLH1SIRT2 | |
| SCHEMBL10421088 | 0.88 | FOLH1 (0.62) | CTRB1PPARAPPARGCTSKTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312260-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2009-12-17 | — | — | US | disclosed |
| US-7605150-B2 | Drug therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1507549-A4 | DRUG THERAPY FOR CELIAC SPRUE | UNIV LELAND STANFORD JUNIOR (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1525188-B1 | NOVEL DERIVATIVES OF 4,4'-DITHIOBIS-(3-AMINOBUTANE-1-SULPHONATES) AND COMPOSITIONS CONTAINING SAME | INST NAT SANTE RECH MED (FR) | 2008-07-09 | — | — | EP | disclosed |
| US-7235687-B2 | Derivatives of 4,4′-dithiobis-(3-aminobutane-1-sulfphonates) and compositions containing same | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2007-06-26 | — | — | US | disclosed |
| US-20060135602-A1 | 4,4'-dithiobis(sodium 3-aminobutane-1-sulfonate)bis chlorohyrate or 4,4'-dithiobis(2,2 dimethylpropyl)-3-aminobutane-1-sulfonate)bis trifluoroacetate for example; treating arterial hypertension | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-06-22 | — | — | US | disclosed |
| US-20060035838-A1 | Drug therapy for celiac sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-02-16 | — | — | US | disclosed |
| EP-1525188-A2 | NOVEL DERIVATIVES OF 4,4'-DITHIOBIS-(3-AMINOBUTANE-1-SULPHONATES) AND COMPOSITIONS CONTAINING SAME | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2005-04-27 | — | — | EP | disclosed |
| EP-1507549-A2 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2005-02-23 | — | — | EP | disclosed |
| EP-1109928-A4 | ENZYMATIC OXIDATIVE DEAMINATION PROCESS | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003096979-A2 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2003-11-27 | — | — | WO | disclosed |
| US-6649387-B2 | From dipeptides | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-18 | — | — | US | disclosed |
| US-6515170-B1 | The present invention concerns an enzymatic oxidative deamination process to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity. | BRISTOL-MYERS SQUIBB CO. | 2003-02-04 | — | — | US | disclosed |
| US-20020025566-A1 | Enzymatic oxidative deamination process | PATEL RAMESH N (US) | 2002-02-28 | — | — | US | disclosed |
| US-6261810-B1 | PREPARING SPECIFIC AMINO LACTAM COMPOUND BY CONTACTING DIPEPTIDE MONOMER WITH AMINOTRANSFERASE IN PRESENCE OF ALPHA-KETOGLUTARATE; FORMING CHEMICAL INTERMEDIATES OF INHIBITORS OF ENDOPEPTIDASE AND ANGIOTENSIN CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | disclosed |
| EP-1109928-A1 | ENZYMATIC OXIDATIVE DEAMINATION PROCESS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6162913-A | Preparation of [4S-(4α,7α,10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido[2,1 -b] [1,3]thiazepine-7-carboxylic acid, methyl ester and salts thereof via novel disulfides | BRISTOL-MYERS SQUIBB CO. (US) | 2000-12-19 | — | — | US | disclosed |
| WO-2000014265-A1 | ENZYMATIC OXIDATIVE DEAMINATION PROCESS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-03-16 | — | — | WO | disclosed |
| US-4560795-A | α-Halomethyl derivatives of α-amino acids | Merrell Dow France et Cie. (FR) | 1985-12-24 | — | — | US | disclosed |
| US-4438270-A | DECARBOXYLASE INHIBITORS | MERRELL TORAUDE ET COMPAGNIE (FR) | 1984-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135602-A1 | 4,4'-dithiobis(sodium 3-aminobutane-1-sulfonate)bis chlorohyrate or 4,4'-dithiobis(2,2 dimethylpropyl)-3-aminobutane-1-sulfonate)bis trifluoroacetate for example; treating arterial hypertension | CBS, CTH, BHMT2 | CTRB1 1450/4885PPARA 1483/4885PPARG 1695/4885 |
| US-20020025566-A1 | Enzymatic oxidative deamination process | DNPEP, PEPD, ACE | CTRB1 262/4885PPARA 3784/4885PPARG 4636/4885 |
| US-20060035838-A1 | Drug therapy for celiac sprue | SI, TMPRSS15, DNPEP | CTRB1 137/4885PPARA 4048/4885PPARG 2952/4885 |
| US-20090312260-A1 | DRUG THERAPY FOR CELIAC SPRUE | SI, DNPEP, SPINT2 | CTRB1 72/4885PPARA 3458/4885PPARG 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.